Analyst Expectations For Sutro Biopharma's Future
Portfolio Pulse from Benzinga Insights
Sutro Biopharma (NASDAQ:STRO) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has decreased slightly to $14.0. The company has shown significant revenue growth but faces challenges with profitability and asset utilization.
September 16, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sutro Biopharma has received mostly bullish analyst ratings, with a slight decrease in the average price target to $14.0. The company shows strong revenue growth but struggles with profitability and asset utilization.
The majority of analysts are bullish on Sutro Biopharma, which is positive for short-term stock performance. However, the slight decrease in the average price target and challenges in profitability and asset utilization may temper expectations. The strong revenue growth is a positive indicator for future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100